Market cap and total return leaders

The region’s powerhouses and big producers are sparkling with projects for the future. Most of the companies’ stock-and-dividend returns were down.

June 26, 2008
(Page 5 of 5)

The Chatter: Under Cloues, K-Tron has acquired one company a year, on average, since he became CEO a decade ago. Its steady expansion is mirrored in its stock price in recent years - relentlessly up.


 

INCYTE CORP.

Route 141 & Henry Clay Road, Building E336, Wilmington

www.incyte.com

302-498-6700

Story continues below.

Founded 1991

President/CEO: Paul A. Friedman

NASDAQ: INCY

Market cap: $764 million *

Stock-div return one year: 59.5 percent **

 

Incyte is developing biotech drugs hoping to treat conditions like human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. Among its experimental compounds are potential treatments for myelofibrosis, rheumatoid arthritis, psoriasis, Type 2 diabetes, breast cancer and multiple sclerosis.

The Chatter: Launched in 1991 to develop gene-mapping technology, and once commanding $140 a share, Incyte now pursues small-molecule drugs itself, but hasn't topped $20 in years. Its yearlong stock rise got close, but then turned south recently after an experimental product got a negative review.


 

ERESEARCH TECHNOLOGY INC.

30 S. 17th St., Philadelphia

www.ert.com

215-972-0420

Founded 1977

President/CEO: Michael J. McKelvey

NASDAQ: ERES

Market cap: $810 million *

Stock-div return one year: 58 percent **

 

Working on the back end of drug development, eResearch helps pharmaceutical, biotech and medical-device companies collect and interpret cardiac safety and clinical data. Its products include the EXPeRT Cardiac Safety data-management system and EXPeRT Portal that gives clinical trial researchers and staff real-time access to progress reports. It also provides study initiation, project management, technology- and regulatory-review services.

The Chatter: The worse things got on drug safety in recent years, the better it got for companies like eResearch, which does the testing. Wall Street cheered McKelvey's appointment a year ago and kept buying.


 

FMC CORP.

1735 Market St., Philadelphia

www.fmc.com

215-299-6000

Founded 1884

NYSE: FMC

Chairman/President/CEO: William G. Walter

Market cap: $5.49 billion *

Stock-div return one year:  48.3 percent **

 

A chemical-maker, FMC's crop protection, pest control, and lawn and garden products are sold worldwide. It makes herbicides to protect various crops, turf, and roadsides from weed growth. Its microcrystalline cellulose is used as a drug dry-tablet binder, its carrageenan for thickening and stabilizing food products, and its lithium for batteries, greases and lubricants.

The Chatter: Soda ash, a key ingredient in everything from glass to detergent to agriculture, has gotten pricier as demand soars around the world. And FMC, a big supplier, has thrived.


* As of June 2, 2008
** As of March 31, 2008


 

« Prev | 1 | 2 | 3 | 4 | 5
|
|
|
|
|